Suggested remit: To appraise the clinical and cost effectiveness of bimekizumab within its marketing authorisation for treating ankylosing spondylitis.
ID4010 Axial spondyloarthritis (non-radiographic, active) - bimekizumab and ID4011 Ankylosing spondylitis - bimekizumab have now been combined and will be appraised under ID6245
 
Status Discontinued
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information DHSC referral received
Process TA
ID number 4011

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 May 2023 Discontinued. ID4010 Axial spondyloarthritis (non-radiographic, active) - bimekizumab and ID4011 Ankylosing spondylitis - bimekizumab have now been combined and will be appraised under ID6245
03 November 2022 - 01 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual